Genprex | Investor Presentation Deck | 44 slides

Genprex · 2022-10
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON

Slide inventory

44
every slide · same image gating as the playbook
01
Slide 1
front_matter
03
summarize
04
Uses a two-column comparison layout to highlight clinical focus areas.present_solution
Open slide detailLoop · Aha Moment
05
The slide uses a Gantt-style chart to visualize the progress of drug candidates through discovery, preclinical, and clinical phases.plan_implementation
06
transition
07
The slide uses big-number metrics to establish market scale and commercial validation.size_opportunity
Open slide detailBeat · Attention
08
Uses a biological analogy (brake pedal) to explain gene function.frame_problem
Open slide detailBeat · Need
09
The slide uses a hub-and-spoke diagram to illustrate the three core pillars of the platform.present_solution
Open slide detailBeat · Satisfaction
10
The slide uses a process flow diagram to explain the mechanism of action for the REQORSATM immunogene therapy.present_solution
Open slide detailBeat · Satisfaction
11
The slide uses fluorescence microscopy images to demonstrate the mechanism of action (TUSC2 protein expression).present_solution
Open slide detailBeat · Satisfaction
12
The slide uses a visual process flow to explain the mechanism of action for a biotech product.present_solution
Open slide detailBeat · Satisfaction
13
Includes medical imaging showing metabolic response in a patient.show_traction
Open slide detailBeat · Satisfaction
14
The table displays individual patient outcomes including tumor regression and disease stability.show_traction
Open slide detailBeat · Satisfaction
15
The slide presents two line charts comparing tumor volume over time across different treatment groups. It includes statistical significance markers (p-values) fshow_traction
Open slide detailBeat · Satisfaction
16
The slide outlines a clinical trial methodology comparing combination therapy against monotherapy continuation.plan_implementation
Open slide detailBeat · Satisfaction
17
Clinical trial methodology slide detailing study arms and endpoints.plan_implementation
Open slide detailBeat · Satisfaction
18
The slide uses a Kaplan-Meier survival plot to demonstrate efficacy. The visual comparison of lung tissue provides qualitative support for the quantitative survshow_traction
Open slide detailBeat · Satisfaction
19
The slide uses bioluminescence imaging and bar charts to show immune cell population changes (T cells, NK cells, MDSC, DC).present_solution
Open slide detailBeat · Satisfaction
20
The slide uses TUSC2 as the synonym for REQORSA in the charts. Data shows statistical significance (p-values) for the triple combination.show_traction
Open slide detailBeat · Satisfaction
21
The slide outlines a clinical trial methodology comparing a novel combination therapy against a standard of care control arm.present_framework
22
Clinical trial methodology slide detailing study design and endpoints for two phases.plan_implementation
23
Includes a histological image showing negative TUSC2 expression.present_solution
24
The slide uses a vertical process flow diagram to illustrate strategic focus areas.show_traction
25
transition
26
frame_problem
27
The slide uses a two-column layout to contrast disease burden (left) with market size (right).size_opportunity
28
frame_problem
Open slide detailLoop · Cost Of Inaction
29
The slide uses a timeline to establish the long-standing nature of the problem and positions the new therapy as a transformative solution.frame_problem
30
Includes a diagram illustrating the biological process of alpha-to-beta cell reprogramming.present_solution
31
The slide presents a Glucose Tolerance Test line chart and a bar chart for beta cell mass, demonstrating the efficacy of the AAV8-PM gene therapy.show_traction
32
Includes a line chart showing blood glucose over time and a bar chart showing beta cell mass comparison.show_traction
33
The charts track insulin/carb ratios over time relative to a viral infusion event.show_traction
34
Includes a microscopic image of cells.present_solution
35
transition
36
other
Open slide detailBeat · Action
37
The slide highlights the company management team with headshots and bulleted professional summaries.other
Open slide detailBeat · Action
38
The slide specifically highlights the Scientific Advisory Board rather than the core management team.other
Open slide detailBeat · Action
39
The slide specifically highlights the Clinical Advisory Board rather than the executive management team.other
Open slide detailBeat · Action
40
The slide lists 5 individuals, one of whom has a placeholder for a photo.other
Open slide detailBeat · Action
41
establish_context
Open slide detailBeat · Action
42
The slide uses a two-column layout to contrast past progress with future goals.show_traction
Open slide detailBeat · Action
43
The slide uses a split-screen layout to contrast the high-level vision (left) with specific strategic pillars (right).inspire_vision
44
front_matter